Ampersand Biomedicines Inc. entered into a definitive agreement to acquire AbCheck s.r.o. from Affimed N.V. (NasdaqCM:AFMD) for $6 million on December 28, 2023. Under the terms of the agreement, Ampersand Biomedicines will acquire AbCheck for a purchase price of $6 million, consisting of $5 million in cash to be paid in two tranches, and $1 million in Ampersand common stock, subject to certain adjustments and a holdback. Affimed is also entitled to receive milestone payments from a pre-existing AbCheck partnership. Through the acquisition, AbCheck will become a wholly-owned and independent unit of Ampersand. Monika Maskova and Milan Sivy from PRK Partners s.r.o. advokátní kanceláø provided legal advice to Affimed N.V. in the transaction.

Ampersand Biomedicines Inc. completed the acquisition of AbCheck s.r.o. from Affimed N.V. (NasdaqCM:AFMD) for $6.4 million on December 28, 2023. Sale was completed for a gross purchase price of $6.4 million, consisting of $5.4 million in cash to be paid in two tranches, and $1.0 million to be paid by delivery in a variable number of Ampersand shares subject to certain adjustments.